eIF2B Modulators Resolve Stress-Translation Trade-off
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, leukodystrophies, cancer, inflammatory diseases, musculoskeletal diseases, and metabolic diseases often fail to effectively modulate the integrated stress response (ISR) pathway, particularly the eIF2α phosphorylation event, which is crucial for cellular stress management.
Innovation Solution
Development of compounds, such as those represented by Formula (I) and Formula (II), which act as eIF2B modulators to activate eIF2B and attenuate the ISR signaling pathway, thereby providing a therapeutic approach to these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eIF2α is phosphorylated in response to stress signals, then cellular stress response is activated, but translation initiation is attenuated
Solution Approach 1:
The patent introduces ISRIB compounds as intermediary molecules that bind to eIF2B and stabilize its active conformation. This mediator overcomes the inhibitory effect of phosphorylated eIF2α on eIF2B, allowing GTP exchange to proceed despite stress-induced phosphorylation, thus resolving the contradiction between stress response activation and translation initiation maintenance
Solution Approach 2:
The patent modifies the functional parameters of eIF2B by using ISRIB compounds to increase the affinity between eIF2B and eIF2, and to stabilize the active conformation of eIF2B. This parameter change allows the system to maintain translation initiation capacity even when eIF2α is phosphorylated, resolving the contradiction between stress signaling and protein synthesis
2Reliability
If eIF2B activity is inhibited by phosphorylated eIF2, then ISR pathway is activated, but cellular adaptation to stress is impaired
Solution Approach 1:
ISRIB compounds act as intermediary molecules that bridge the gap between eIF2B and eIF2, stabilizing their interaction and overcoming the inhibition imposed by phosphorylated eIF2α. This allows cells to maintain adaptability to stress while preserving the reliability of ISR pathway activation for stress signaling
Solution Approach 2:
Instead of allowing phosphorylated eIF2α to inhibit eIF2B (the natural stress response), the patent uses ISRIB compounds to invert this interaction by stabilizing the eIF2B-eIF2 complex in an active conformation. This inversion allows cells to adapt to stress while maintaining translation initiation, resolving the contradiction between pathway activation and cellular adaptability
3Reliability
If small molecule therapeutics target eIF2B to modulate ISR, then disease treatment potential is achieved, but molecular mechanism complexity increases
Solution Approach 1:
The patent employs ISRIB small molecules as simple intermediary compounds that bind to eIF2B and stabilize its active conformation. This simple molecular mechanism achieves reliable disease treatment by modulating eIF2B activity without requiring complex therapeutic mechanisms, resolving the contradiction between treatment efficacy and mechanism complexity
Data Source
AI summary
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (I SR) and for treating related diseases, disorders, and conditions.